Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

L. Antonuzzo · SciRah

Researcher profile · Semantic Scholar

L. Antonuzzo

Share profile

L. Antonuzzo — researcher profile on SciRah

h-index: 40
Works: 252
Citations: 5,627

Most-cited papers

Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
J. Heymach, David H. Harpole, T. Mitsudomi, J. Taube +23 more
2023New England Journal of Medicine632 citations Open access
Semantic Scholar
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
C. Antoniotti, D. Rossini, F. Pietrantonio, A. Catteau +33 more
2022The Lancet Oncology207 citations Open access
Semantic Scholar
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial
F. Morano, A. Raimondi, F. Pagani, S. Lonardi +29 more
2022Journal of Clinical Oncology104 citations Open access
Semantic Scholar
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data
M. Rimini, L. Fornaro, S. Lonardi, M. Niger +36 more
2023Liver international (Print)102 citations Open access
Semantic Scholar
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
J. van de Haar, Xu-Hui Ma, S. Ooft, Pim W. van der Helm +46 more
2023Nature Medicine80 citations Open access
Semantic Scholar
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours.
C. Celsa, G. Cabibbo, Claudia Am Fulgenzi, B. Scheiner +68 more
2023Journal of Hepatology63 citations Open access
Semantic Scholar
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors.
T. El Zarif, A. Nassar, G. Pond, T. Zhuang +51 more
2023Journal of the National Cancer Institute57 citations Open access
Semantic Scholar
Exploiting Tertiary Lymphoid Structures to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy
Giulia Petroni, S. Pillozzi, L. Antonuzzo
2024Cancer Research50 citations Open access
Semantic Scholar
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study
C. Antoniotti, D. Rossini, F. Pietrantonio, L. Salvatore +23 more
2024Journal of Clinical Oncology49 citations
Semantic Scholar
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO
D. Rossini, C. Antoniotti, S. Lonardi, F. Pietrantonio +24 more
2022Journal of Clinical Oncology47 citations Open access
Semantic Scholar
Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine
F. di Costanzo, F. Di Costanzo, L. Antonuzzo, E. Mazza +1 more
2023Cancers40 citations Open access
Semantic Scholar
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience
A. Boccaccino, B. Borelli, R. Intini, M. Antista +21 more
2022ESMO Open31 citations Open access
Semantic Scholar
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation
S. Lonardi, C. Rasola, R. Lobefaro, D. Rossini +23 more
2023Journal of Clinical Oncology30 citations Open access
Semantic Scholar
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry
A. Cortellini, J. Tabernero, U. Mukherjee, R. Salazar +123 more
2023The Lancet Oncology29 citations Open access
Semantic Scholar
Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study
F. Nappo, L. Fornaro, L. Pompella, S. Catanese +19 more
2023Journal of Cancer Research and Clinical Oncology28 citations Open access
Semantic Scholar
Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer
D. Lavacchi, S. Fancelli, G. Roviello, F. Castiglione +10 more
2022Frontiers in Oncology28 citations Open access
Semantic Scholar
Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy.
E. Caliman, S. Fancelli, Carlotta Ottanelli, F. Mazzoni +10 more
2022Cancer Treatment and Research Communications28 citations Open access
Semantic Scholar
The CAIX inhibitor SLC-0111 exerts anti-cancer activity on gastric cancer cell lines and resensitizes resistant cells to 5-Fluorouracil, taxane-derived, and platinum-based drugs.
E. Andreucci, A. Biagioni, S. Peri, G. Versienti +16 more
2023Cancer Letters26 citations Open access
Semantic Scholar
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study
M. Rimini, G. Masi, S. Lonardi, F. Nichetti +45 more
2024Targeted oncology25 citations Open access
Semantic Scholar
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).
J. Yang, Meng-Zhao Wang, L. Doucet, Yun Fan +44 more
2025Journal of Clinical Oncology23 citations
Semantic Scholar
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience
M. Rimini, V. Burgio, L. Antonuzzo, L. Rimassa +14 more
2023Therapeutic Advances in Medical Oncology21 citations Open access
Semantic Scholar
Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer
D. Lavacchi, G. Roviello, Alessia Guidolin, S. Romano +8 more
2023International Journal of Molecular Sciences18 citations Open access
Semantic Scholar
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial
F. Piscaglia, G. Masi, E. Martinelli, G. Cabibbo +18 more
2025ESMO Open16 citations
Semantic Scholar
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas.
C. Liverani, Alberto Bongiovanni, F. Foca, F. Bergamo +25 more
2024European Journal of Cancer16 citations Open access
Semantic Scholar
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV.
F. Pietrantonio, F. Bergamo, D. Rossini, F. Ghelardi +16 more
2023European Journal of Cancer16 citations Open access
Semantic Scholar
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma
L. Procaccio, V. Merz, M. Fasano, V. Vaccaro +20 more
2023Cancer Medicine15 citations Open access
Semantic Scholar
Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab
M. Catalano, S. E. Rebuzzi, M. Maruzzo, U. de Giorgi +30 more
2023JAMA Network Open15 citations Open access
Semantic Scholar
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)
D. Ciardiello, C. Chiarazzo, V. Famiglietti, A. Damato +29 more
2022ESMO Open15 citations Open access
Semantic Scholar
Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing
D. Lavacchi, S. Fancelli, E. Buttitta, Gianmarco Vannini +10 more
2023International Journal of Molecular Sciences14 citations Open access
Semantic Scholar
Dermoscopy as a Tool for Identifying Potentially Metastatic Thin Melanoma: A Clinical–Dermoscopic and Histopathological Case–Control Study
V. de Giorgi, F. Silvestri, Giovanni Cecchi, F. Venturi +10 more
2024Cancers12 citations Open access
Semantic Scholar
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study
C. Pinto, A. Orlandi, Nicola Normanno, E. Maiello +16 more
2024Journal of Clinical Oncology12 citations Open access
Semantic Scholar
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population
Federica Lo Prinzi, F. Salani, M. Rimini, M. Rizzato +62 more
2024The Oncologist12 citations Open access
Semantic Scholar
READY: Real-world data from an Italian compassionate use program of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC).
L. Antonuzzo, M. Maruzzo, U. de Giorgi, D. Santini +16 more
2023Journal of Clinical Oncology12 citations Open access
Semantic Scholar
Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors
G. Roviello, M. Catalano, U. de Giorgi, M. Maruzzo +13 more
2022Frontiers in Oncology12 citations Open access
Semantic Scholar
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index
M. Persano, M. Rimini, F. Salani, F. L. Prinzi +69 more
2025Liver international (Print)11 citations Open access
Semantic Scholar
Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25).
Elisabetta Gambale, M. Maruzzo, C. Messina, I. de Gennaro Aquino +27 more
2024Clinical Genitourinary Cancer11 citations Open access
Semantic Scholar
Personalized Medicine for Metastatic Prostate Cancer: The Paradigm of PARP Inhibitors.
B. Maiorano, V. Conteduca, M. Catalano, L. Antonuzzo +3 more
2023Critical reviews in oncology/hematology11 citations Open access
Semantic Scholar
Platinum-based chemotherapy in metastatic prostate cancer: what possibilities?
M. Catalano, A. Lapucci, S. Nobili, I. de Gennaro Aquino +6 more
2023Cancer Chemotherapy and Pharmacology11 citations Open access
Semantic Scholar
Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment
Elisabetta Gambale, S. Fancelli, E. Caliman, M. Petrella +3 more
2022Journal for ImmunoTherapy of Cancer11 citations Open access
Semantic Scholar
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRI
V. Nasca, F. Bergamo, L. Foltran, L. Antonuzzo +18 more
2025BMC Cancer10 citations Open access
Semantic Scholar
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey
M. Reni, E. Giommoni, F. Bergamo, M. Milella +157 more
2023ESMO Open10 citations Open access
Semantic Scholar
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study
L. Cantini, F. Paoloni, Federica Pecci, F. Spagnolo +47 more
2023Journal of the National Cancer Institute10 citations Open access
Semantic Scholar
Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study
M. Catalano, S. E. Rebuzzi, M. Maruzzo, U. de Giorgi +30 more
2024Frontiers in Immunology9 citations Open access
Semantic Scholar
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab
M. Rimini, Eleonora Loi, M. Rizzato, T. Pressiani +25 more
2024Targeted oncology9 citations
Semantic Scholar
KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population
S. Fancelli, E. Caliman, F. Mazzoni, L. Paglialunga +14 more
2022Frontiers in Oncology9 citations Open access
Semantic Scholar
Gender matters. Sex-related differences in immunotherapy outcome in patients with non-small cell lung cancer.
L. Antonuzzo, E. Caliman, M. Petrella, Virginia Rossi +7 more
2022Current Cancer Drug Targets9 citations Open access
Semantic Scholar
Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice
G. Roviello, M. Catalano, Carlotta Ottanelli, R. Giorgione +5 more
2022Medical Oncology9 citations Open access
Semantic Scholar
Early changes in circulating tumor DNA (ctDNA) predict treatment response in metastatic KRAS-mutated colorectal cancer (mCRC) patients
D. Lavacchi, Stefania Gelmini, Adele Calabri, G. Rossi +11 more
2023Heliyon8 citations Open access
Semantic Scholar
Liquid biopsy in colorectal cancer: No longer young, but not yet old
G. Roviello, D. Lavacchi, L. Antonuzzo, M. Catalano +1 more
2022World Journal of Gastroenterology8 citations Open access
Semantic Scholar
Prognostic role of hERG1 Potassium Channels in Neuroendocrine Tumours of the Ileum and Pancreas
J. Iorio, L. Antonuzzo, E. Scarpi, M. D'Amico +14 more
2022International Journal of Molecular Sciences7 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Lonardi×15
Invite
S. Lonardi — researcher profile on SciRah
D. Lavacchi×15
Invite
D. Lavacchi — researcher profile on SciRah
F. Bergamo×14
Invite
F. Bergamo — researcher profile on SciRah
G. Roviello×13
Invite
G. Roviello — researcher profile on SciRah

×11

Invite

S. Pillozzi — researcher profile on SciRah

Invite

E. Caliman — researcher profile on SciRah

M. Scartozzi×9

Invite

M. Scartozzi — researcher profile on SciRah

Invite

L. Rimassa — researcher profile on SciRah

Invite

S. Tamberi — researcher profile on SciRah

F. Pietrantonio×7

Invite

F. Pietrantonio — researcher profile on SciRah

C. Cremolini×7

Invite

C. Cremolini — researcher profile on SciRah

Invite

M. Niger — researcher profile on SciRah